LBRX — LB Pharmaceuticals Inc price, chart and key statistics

Price data

Price

$41.00

YTD price return

+84.19%

YTD total return

+84.19%

Next earnings

Nov 5, 2026

Market cap

1.3B2025-09 399.5M2026-10 1.3B+231.1% over the window

Enterprise value

1B

Shares outstanding

32.3M2025-09 25.3M2026-06 32.3M+27.5% over the window

52W low

$14.32

52W high

$50.16

From 52W high

-18.26%

From 52W low

+186.37%

52W range

74%

Volume

Rel volume

0.92×

30D volume

421.4K

30D $ vol

16.1M

Fundamentals

EPS (ttm)

-$2.842024-12 -$176.152026-06 -$2.84-98.4% over the window

FCF (ttm)

-82.8M2024-12 -53.8M2026-06 -82.8M+53.9% over the window

FCF/share

-$2.572025-12 -$1.232026-06 -$2.57+108.8% over the window

Book value/share

$10.302025-03 -$3.932026-06 $10.30-362.4% over the window

ROE

-25.78%2025-12 -8.4%2026-06 -25.8%+208.2% over the window

ROA

-23.69%2024-12 -188.2%2026-06 -23.7%-87.4% over the window

Current ratio

15.082024-12 3.562026-06 15.08+323.4% over the window

Per-share growth (CAGR, ttm) · 10Y

Price

+156.42%2025-10-20 → 2026-10-20$16.00 → $41.00 (+156.3% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.n/an/an/a

Total return

+156.42%2025-10-20 → 2026-10-20$16.00 → $41.00 (+156.3% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.n/an/an/a

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.

-14.4×2025-09 -6.332026-10 -15.44+143.8% over the window

Fwd P/E

-8.0×

P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.

4.0×2025-09 1.292026-10 3.98+209.1% over the window

FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.

-6.26%2025-12 -5.5%2026-06 -7.9%+43.2% over the window

Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($0) ÷ today's market cap ($1.3B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.

0.00%2025-12 0.0%2026-06 0.0%

Shareholder yield (cash, ttm)(TTM buybacks net of issuance $0 + TTM dividends $0) ÷ today's market cap ($1.3B). Same caveat as the cash buyback yield.

0.00%2025-12 0.0%2026-06 0.0%